Literature DB >> 36138190

Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis.

Amir A Razmjou1, Jennifer M Wang2, Ani Shahbazian2, Srinivasa Reddy2, Christina Charles-Schoeman2.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA)-associated lung disease (LD) associates with significantly increased morbidity and mortality. Although oxidative stress plays an important role in the inflammatory responses in other forms of lung disease, minimal work has evaluated its role in RA-LD. The current work examines the relationship between the anti-oxidant HDL-associated enzyme paraoxonase-1 (PON1), the PON1 Q192R polymorphism, and a targeted oxylipin panel with RA-LD.
METHODS: This study was conducted as a retrospective chart review of a longitudinal single-center cohort of 250 RA patients. CT scans of the chest were reviewed by the interpreting radiologist and classified as small airways disease (SAD), interstitial lung disease (ILD), and bronchiectasis. PON1 activity was measured by its lactonase, arylesterase, and paraoxonase functions. The PON1 Q192R polymorphism and a targeted lipidomics panel were performed as previously reported.
RESULTS: 43.2% of the 250 RA patient cohort (n = 108) had available CT scans, including 48 patients (44.4%) with SAD, 27 patients (25.0%) with bronchiectasis, and 16 patients (14.8%) with ILD. Patients with SAD had significantly lower baseline PON1 activity by its arylesterase, and lactonase functions, as well as higher 15-HETE, LTB4, and PGE2 levels compared to those without SAD. These predictors of SAD remained significant after multivariate analysis including known risk factors for RA-LD. Suppressed PON1 activity also correlated with higher levels of 15-HETE and 12-HETE.
CONCLUSION: In a single-center RA cohort, suppressed baseline PON1 activity and elevation in the oxylipins 15-HETE, LTB4, and PGE2 predicted the presence of RA-SAD in longitudinal follow-up. Key Points • Small airways disease (SAD) was present in 44.4% of this rheumatoid arthritis (RA) cohort. • Patients with SAD had significantly lower baseline PON1 activity, as well as higher levels of the oxylipins 15-HETE, LTB4, and PGE2 levels compared to those without SAD. • Further work is warranted to confirm these findings and further define the role of PON1 and lipid oxidation in RA lung disease.
© 2022. The Author(s).

Entities:  

Keywords:  Paraoxonase-1; Rheumatoid arthritis; Small airways disease

Year:  2022        PMID: 36138190     DOI: 10.1007/s10067-022-06375-w

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  35 in total

Review 1.  Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity.

Authors:  Maarten Boers; Ben Dijkmans; Sherine Gabriel; Hilal Maradit-Kremers; James O'Dell; Theodore Pincus
Journal:  Arthritis Rheum       Date:  2004-06

Review 2.  Paraoxonase and atherosclerosis.

Authors:  P N Durrington; B Mackness; M I Mackness
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

3.  Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.

Authors:  Daniel H Solomon; Elizabeth W Karlson; Eric B Rimm; Carolyn C Cannuscio; Lisa A Mandl; JoAnn E Manson; Meir J Stampfer; Gary C Curhan
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

4.  High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory.

Authors:  Nima M Gharavi; Peter S Gargalovic; Irene Chang; Jesus A Araujo; Michael J Clark; Wan Lam Szeto; Andrew D Watson; Aldons J Lusis; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-03-22       Impact factor: 8.311

Review 5.  Mechanisms of lung disease development in rheumatoid arthritis.

Authors:  Dan Wang; Jie Zhang; Jessica Lau; Shaohua Wang; Veena Taneja; Eric L Matteson; Robert Vassallo
Journal:  Nat Rev Rheumatol       Date:  2019-08-27       Impact factor: 20.543

6.  Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis.

Authors:  Christina Charles-Schoeman; Yuen Yin Lee; Ani Shahbazian; Alan H Gorn; John Fitzgerald; Veena K Ranganath; Mihaela Taylor; Nagesh Ragavendra; Maureen McMahon; David Elashoff; Srinivasa T Reddy
Journal:  Arthritis Rheum       Date:  2013-11

7.  Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction.

Authors:  Lorenz M Fischer; Raymond G Schlienger; Christian Matter; Hershel Jick; Christoph R Meier
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

Review 8.  Rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Anne Barton; Gerd R Burmester; Paul Emery; Gary S Firestein; Arthur Kavanaugh; Iain B McInnes; Daniel H Solomon; Vibeke Strand; Kazuhiko Yamamoto
Journal:  Nat Rev Dis Primers       Date:  2018-02-08       Impact factor: 52.329

Review 9.  Cardiovascular disease and rheumatoid arthritis: an update.

Authors:  Christina Charles-Schoeman
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

10.  Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.

Authors:  Sicong Huang; Vanessa L Kronzer; Paul F Dellaripa; Kevin D Deane; Marcy B Bolster; Vivek Nagaraja; Dinesh Khanna; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Treatm Opt Rheumatol       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.